Roth Positive on TG Therapeutics (TGTX) Following Q3 Results; Expects Strong ASH Showing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
November 10, 2014 4:15 PM ESTNEW YORK, Nov. 10, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq: TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for cancer and autoimmune diseases, today announced its results for the third quarter ended September 30, 2014 and recent company developments.
Financial Results for the Third Quarter 2014
At September 30, 2014 the Company had cash, cash equivalents, investment securities, and interest receivable of $67.3 million, which includes approximately $22.8 million of net proceeds from the utilization of the Company's at-the-market ("ATM") sales facility during the third quarter, as compared to $45.4 million at December... More
